109 related articles for article (PubMed ID: 15646067)
21. Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients.
Turner D; Brenner BG; Routy JP; Petrella M; Wainberg MA
New Microbiol; 2004 Apr; 27(2 Suppl 1):31-9. PubMed ID: 15646062
[TBL] [Abstract][Full Text] [Related]
22. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
[TBL] [Abstract][Full Text] [Related]
23. Genotypic resistance tests for the clinical management of patients with primary HIV infection.
Narciso P; Lazzarin A
Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588
[TBL] [Abstract][Full Text] [Related]
24. Development of drug resistance mutations in patients on highly active antiretroviral therapy: does competitive advantage drive evolution.
Kolber MA
AIDS Rev; 2007; 9(2):68-74. PubMed ID: 17694674
[TBL] [Abstract][Full Text] [Related]
25. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
[TBL] [Abstract][Full Text] [Related]
26. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy.
Chiappini E; Galli L; Zazzi M; de Martino M
J Med Virol; 2003 Aug; 70(4):506-12. PubMed ID: 12794711
[TBL] [Abstract][Full Text] [Related]
27. The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population.
Pillay D
Antivir Ther; 2001; 6 Suppl 3():15-24. PubMed ID: 11678470
[TBL] [Abstract][Full Text] [Related]
28. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
Fun A; Van Baelen K; van Lelyveld SF; Schipper PJ; Stuyver LJ; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2010 Nov; 65(11):2300-4. PubMed ID: 20736234
[TBL] [Abstract][Full Text] [Related]
29. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.
Theys K; Deforche K; Vercauteren J; Libin P; van de Vijver DA; Albert J; Asjö B; Balotta C; Bruckova M; Camacho RJ; Clotet B; Coughlan S; Grossman Z; Hamouda O; Horban A; Korn K; Kostrikis LG; Kücherer C; Nielsen C; Paraskevis D; Poljak M; Puchhammer-Stockl E; Riva C; Ruiz L; Liitsola K; Schmit JC; Schuurman R; Sönnerborg A; Stanekova D; Stanojevic M; Struck D; Van Laethem K; Wensing AM; Boucher CA; Vandamme AM;
Retrovirology; 2012 Oct; 9():81. PubMed ID: 23031662
[TBL] [Abstract][Full Text] [Related]
30. Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals.
Weber J; Gibson RM; Sácká L; Strunin D; Hodek J; Weberová J; Pávová M; Alouani DJ; Asaad R; Rodriguez B; Lederman MM; Quiñones-Mateu ME
AIDS Res Ther; 2017; 14():15. PubMed ID: 28331526
[TBL] [Abstract][Full Text] [Related]
31. Human immunodeficiency virus type 1 fitness and tropism: concept, quantification, and clinical relevance.
Clementi M; Lazzarin A
Clin Microbiol Infect; 2010 Oct; 16(10):1532-8. PubMed ID: 20678176
[TBL] [Abstract][Full Text] [Related]
32. Fitness of drug resistant HIV-1: methodology and clinical implications.
Quiñones-Mateu ME; Arts EJ
Drug Resist Updat; 2002 Dec; 5(6):224-33. PubMed ID: 12531179
[TBL] [Abstract][Full Text] [Related]
33. Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.
Buckheit RW
Expert Opin Investig Drugs; 2004 Aug; 13(8):933-58. PubMed ID: 15268633
[TBL] [Abstract][Full Text] [Related]
34. Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness.
Weber J; Weberova J; Carobene M; Mirza M; Martinez-Picado J; Kazanjian P; Quiñones-Mateu ME
J Virol Methods; 2006 Sep; 136(1-2):102-17. PubMed ID: 16690137
[TBL] [Abstract][Full Text] [Related]
35. Fitness variations and their impact on the evolution of antiretroviral drug resistance.
Menéndez-Arias L; Martínez MA; Quiñones-Mateu ME; Martinez-Picado J
Curr Drug Targets Infect Disord; 2003 Dec; 3(4):355-71. PubMed ID: 14754435
[TBL] [Abstract][Full Text] [Related]
36. An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugs.
van Maarseveen NM; de Jong D; Boucher CA; Nijhuis M
J Acquir Immune Defic Syndr; 2006 Jun; 42(2):162-8. PubMed ID: 16645546
[TBL] [Abstract][Full Text] [Related]
37. HIV recombination: what is the impact on antiretroviral therapy?
Fraser C
J R Soc Interface; 2005 Dec; 2(5):489-503. PubMed ID: 16849208
[TBL] [Abstract][Full Text] [Related]
38. Practical applications of viral fitness in clinical practice.
Bates M; Wrin T; Huang W; Petropoulos C; Hellmann N
Curr Opin Infect Dis; 2003 Feb; 16(1):11-8. PubMed ID: 12821824
[TBL] [Abstract][Full Text] [Related]
39. Enhanced replicative capacity and pathogenicity of HIV-1 isolated from individuals infected with drug-resistant virus and declining CD4+ T-cell counts.
Solomon A; Lane N; Wightman F; Gorry PR; Lewin SR
J Acquir Immune Defic Syndr; 2005 Oct; 40(2):140-8. PubMed ID: 16186730
[TBL] [Abstract][Full Text] [Related]
40. Modelling the impact of acute infection dynamics on the accumulation of HIV-1 mutations.
Shiri T; Welte A
J Theor Biol; 2011 Jun; 279(1):44-54. PubMed ID: 21420419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
